First Amendment

Showing 1041 articles
Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

The Hartford Caps "Outstanding" 2025 with Strong Underwriting, AI Push, and Robust Shareholder Returns

The Hartford Financial Services Group reported robust fourth-quarter and full-year 2025 results, driven by profitable underwriting growth, higher investment income, and disciplined capital management. CEO Chris Swift outlined a strategic shift towards an "AI-first" operational model while signaling confidence in sustained margins and growth across business and personal lines.

Business

Cavco Industries Posts Strong Q1 2026 Results on Surging Demand and Strategic Execution

Cavco Industries (CVCO) reported robust first-quarter fiscal 2026 earnings, with revenue climbing 9.5% year-over-year and operating profit jumping approximately 50%. The manufactured housing leader credited strategic production increases, improved pricing, and a rebound in its financial services segment for the strong performance, while also highlighting its pending acquisition of American Homestar.